🚀 VC round data is live in beta, check it out!
Regeneron Valuation Multiples
Discover revenue and EBITDA valuation multiples for Regeneron and similar public comparables like Merck KGaA, Chugai Pharma, Takeda Pharmaceuticals, UCB and more.
Regeneron Overview
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Founded
1988
HQ
Employees
15.4K
Website
Sectors
Financials (LTM)
EV
$78B
Regeneron Financials
Regeneron reported last 12-month revenue of $15B and EBITDA of $5B.
In the same LTM period, Regeneron generated $14B in gross profit, $5B in EBITDA, and $5B in net income.
Revenue (LTM)
Regeneron P&L
In the most recent fiscal year, Regeneron reported revenue of $14B and EBITDA of $6B.
Regeneron expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15B | XXX | $14B | XXX | XXX | XXX |
| Gross Profit | $14B | XXX | $12B | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $5B | XXX | $6B | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 41% | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| Net Profit | $5B | XXX | $5B | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 34% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Regeneron Stock Performance
Regeneron has current market cap of $84B, and enterprise value of $78B.
Market Cap Evolution
Regeneron's stock price is $790.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78B | $84B | 0.0% | XXX | XXX | XXX | $46.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRegeneron Valuation Multiples
Regeneron trades at 5.3x EV/Revenue multiple, and 14.9x EV/EBITDA.
EV / Revenue (LTM)
Regeneron Financial Valuation Multiples
As of March 7, 2026, Regeneron has market cap of $84B and EV of $78B.
Equity research analysts estimate Regeneron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Regeneron has a P/E ratio of 17.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84B | XXX | $84B | XXX | XXX | XXX |
| EV (current) | $78B | XXX | $78B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 14.9x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBIT | 15.9x | XXX | 16.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | 6.3x | XXX | XXX | XXX |
| P/E | 17.0x | XXX | 17.1x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 13.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Regeneron Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Regeneron Margins & Growth Rates
Regeneron's revenue in the last 12 month grew by 10%.
Regeneron's revenue per employee in the last FY averaged $0.9M.
Regeneron's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Regeneron's rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Regeneron Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | (9%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 40% | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Regeneron Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Merck KGaA | XXX | XXX | XXX | XXX | XXX | XXX |
| Chugai Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Takeda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| UCB | XXX | XXX | XXX | XXX | XXX | XXX |
| Zoetis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regeneron M&A Activity
Regeneron acquired XXX companies to date.
Last acquisition by Regeneron was on XXXXXXXX, XXXXX. Regeneron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Regeneron
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRegeneron Investment Activity
Regeneron invested in XXX companies to date.
Regeneron made its latest investment on XXXXXXXX, XXXXX. Regeneron invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Regeneron
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Regeneron
| When was Regeneron founded? | Regeneron was founded in 1988. |
| Where is Regeneron headquartered? | Regeneron is headquartered in United States. |
| How many employees does Regeneron have? | As of today, Regeneron has over 15K employees. |
| Who is the CEO of Regeneron? | Regeneron's CEO is Leonard S. Schleifer. |
| Is Regeneron publicly listed? | Yes, Regeneron is a public company listed on Nasdaq. |
| What is the stock symbol of Regeneron? | Regeneron trades under REGN ticker. |
| When did Regeneron go public? | Regeneron went public in 1991. |
| Who are competitors of Regeneron? | Regeneron main competitors are Merck KGaA, Chugai Pharma, Takeda Pharmaceuticals, UCB. |
| What is the current market cap of Regeneron? | Regeneron's current market cap is $84B. |
| What is the current revenue of Regeneron? | Regeneron's last 12 months revenue is $15B. |
| What is the current revenue growth of Regeneron? | Regeneron revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Regeneron? | Current revenue multiple of Regeneron is 5.3x. |
| Is Regeneron profitable? | Yes, Regeneron is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Regeneron? | Regeneron's last 12 months EBITDA is $5B. |
| What is Regeneron's EBITDA margin? | Regeneron's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Regeneron? | Current EBITDA multiple of Regeneron is 14.9x. |
| What is the current FCF of Regeneron? | Regeneron's last 12 months FCF is $6B. |
| What is Regeneron's FCF margin? | Regeneron's last 12 months FCF margin is 38%. |
| What is the current EV/FCF multiple of Regeneron? | Current FCF multiple of Regeneron is 14.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.